317 research outputs found
Author Response: Early Neurologic Deterioration in Lacunar Stroke: Clinical and Imaging Predictors and Association With Long-term Outcome
No full textsj-pdf-1-eso-10.1177_23969873211061975 – Supplemental Material for Intracerebral haemorrhage volume, haematoma expansion and 3-month outcomes in patients on antiplatelets. A systematic review and meta-analysis
No full textSupplemental Material, sj-pdf-1-eso-10.1177_23969873211061975 for Intracerebral haemorrhage volume, haematoma expansion and 3-month outcomes in patients on antiplatelets. A systematic review and meta-analysis by Martina B Goeldlin, Bernhard M Siepen, Madlaine Mueller, Bastian Volbers, Werner Z’Graggen, David Bervini, Andreas Raabe, Nikola Sprigg, Urs Fischer and David J Seiffge in European Stroke Journal</p
Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
No full textAtrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients with atrial fibrillation and stroke aims to reduce the risk of recurrent ischaemic stroke. Findings from randomised controlled trials assessing the optimal timing to introduce direct oral anticoagulant therapy after a stroke show that early start (ie, within 48 h for minor to moderate strokes and within 4-5 days for large strokes) seems safe and could reduce the risk of early recurrence. Other promising developments regarding early rhythm control, left atrial appendage occlusion, and novel factor XI inhibitor oral anticoagulants suggest that these therapies have the potential to further reduce the risk of stroke. Secondary prevention strategies in patients with atrial fibrillation who have a stroke despite oral anticoagulation therapy is an unmet medical need. Research advances suggest a heterogeneous spectrum of causes, and ongoing trials are investigating new approaches for secondary prevention in this vulnerable patient group. In patients with atrial fibrillation and a history of intracerebral haemorrhage, the latest data from randomised controlled trials on stroke prevention shows that oral anticoagulation reduces the risk of ischaemic stroke but more data are needed to define the safety profile
No Safety Concerns Over Transfusion of Red Blood Cell Concentrates in Patients With Intracerebral Hemorrhage
No full text
sj-docx-1-wso-10.1177_17474930211062478 – Supplemental material for MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage
No full textSupplemental material, sj-docx-1-wso-10.1177_17474930211062478 for MRI and CT imaging biomarkers of cerebral amyloid angiopathy in lobar intracerebral hemorrhage by Ghil Schwarz, Gargi Banerjee, Isabel C Hostettler, Gareth Ambler, David J Seiffge, Hatice Ozkan, Simone Browning, Robert Simister, Duncan Wilson, Hannah Cohen, Tarek Yousry, Rustam Al-Shahi Salman, Gregory Y H Lip, Martin M Brown, Keith W Muir, Henry Houlden, Rolf Jäger and David J Werring in International Journal of Stroke</p
Association between the Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage (ICH) associated with cerebral amyloid angiopathy and the risk of recurrent ICH: outline protocol for a population-based analysis, and external validation in a hospital-based cohort
No full textThis is an outline protocol for a study assessing the association between the Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage (ICH) associated with cerebral amyloid angiopathy and the risk of recurrent ICH.Rodrigues, Mark; Seiffge, David; Werring, David; Al-Shahi Salman, Rustam. (2018). Association between the Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage (ICH) associated with cerebral amyloid angiopathy and the risk of recurrent ICH: outline protocol for a population-based analysis, and external validation in a hospital-based cohort, [text]. https://doi.org/10.7488/ds/7479
sj-docx-1-eso-10.1177_23969873231187444 – Supplemental material for Management of covert brain infarction survey: A call to care for and trial this neglected population
No full textSupplemental material, sj-docx-1-eso-10.1177_23969873231187444 for Management of covert brain infarction survey: A call to care for and trial this neglected population by Thomas R Meinel, Camilla B Triulzi, Johannes Kaesmacher, Adnan Mujanovic, Marco Pasi, Lester Y Leung, David M Kent, Yi Sui, David Seiffge, Philipp Bücke, Roza Umarova, Marcel Arnold, Laurent Roten, Thanh N Nguyen, Joanna Wardlaw and Urs Fischer in European Stroke Journal</p
[Atrial fibrillation and ischaemic stroke: current treatment and personalized risk prediction of intracerebral haemorrhage].
No full textAtrial fibrillation and ischaemic stroke: current treatment and personalized risk prediction of intracerebral haemorrhage Abstract. Atrial fibrillation is a major cause of stroke. Management of patients with atrial fibrillation and stroke is challenging. In this review article, based on the most recent scientific literature, the following questions are discussed: 1) When is the optimal point in time to start anticoagulation after a recent stroke? 2) How to treat patients with atrial fibrillation that have a stroke despite anticoagulant therapy? 3) What is the added value of MRI for personalized risk-prediction of intracerebral hemorrhage? 4) How to treat patients with atrial fibrillation after intracerebral hemorrhage? We provide recommendations for daily clinical management
Hematoma location and morphology of anticoagulation-associated intracerebral hemorrhage
No full textObjective To study hematoma location and morphology of intracerebral hemorrhage (ICH) associated with oral anticoagulants (OAC) and delineate causes and mechanism. Methods We performed a systematic literature research and meta-analysis of studies comparing neuroimaging findings in patients with OAC-ICH compared to those with ICH not associated with OAC (non-OAC ICH). We calculated pooled risk ratios (RRs) for ICH location using the Mantel-Haenszel random-effects method and corresponding 95% confidence intervals (95% CI). Results We identified 8 studies including 6,259 patients (OAC-ICH n = 1,107, pooled OAC-ICH population 17.7%). There was some evidence for deep ICH location (defined as ICH in the thalamus, basal ganglia, internal capsule, or brainstem) being less frequent in patients with OAC-ICH (OAC-ICH: 450 of 1,102/40.8% vs non-OAC ICH: 2,656 of 4,819/55.1%; RR 0.94, 95% CI 0.88-1.00, p = 0.05, I-2 = 0%) while cerebellar ICH location was significantly more common in OAC-ICH (OAC-ICH: 111 of 1,069/10.4% vs non-OAC ICH: 326 of 4,787/6.8%; RR 1.45, 95% CI 1.12-1.89, p = 0.005, I-2 = 21%) compared to non-OAC ICH. There was no statistically significant relationship to OAC use for lobar (OAC-ICH: 423 of 1,107/38.2% vs non-OAC ICH: 1,884 of 5,152/36.6%; RR 1.02, 95% CI 0.89-1.17, p = 0.75, I-2 = 53%, p for heterogeneity = 0.04) or brainstem ICH (OAC-ICH: 36 of 546/6.6% vs non-OAC ICH: 172 of 2,626/6.5%; RR 1.04, 95% CI 0.58-1.87, p = 0.89, I-2 = 59%, p for heterogeneity = 0.04). The risk for intraventricular extension (OAC-ICH: 436 of 840/51.9% vs non-OAC ICH: 1,429 of 3,508/40.7%; RR 1.26, 95% CI 1.16-1.36, p < 0.001, I-2 = 0%) was significantly increased in patients with OAC-ICH. We found few data on ICH morphology in OAC-ICH vs non-OAC ICH. Conclusion The overrepresentation of cerebellar ICH location and intraventricular extension in OAC-ICH might have mechanistic relevance for the underlying arteriopathy, pathophysiology, or bleeding pattern of OAC-ICH, and should be investigated further
- …
